Perceptive Advisors LLC Increases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX

Posted by Stanley Muller on Jun 18th, 2026

Perceptive Advisors LLC raised its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Free Report) by 31.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,350,425 shares of the company’s stock after acquiring an additional 320,291 shares during the period. Protagonist Therapeutics makes up 2.1% of Perceptive Advisors LLC’s holdings, making the stock its 10th largest position. Perceptive Advisors LLC’s holdings in Protagonist Therapeutics were worth $117,946,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its stake in Protagonist Therapeutics by 110.6% during the 4th quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock valued at $26,000 after acquiring an additional 156 shares in the last quarter. Greenline Wealth Management LLC bought a new stake in Protagonist Therapeutics during the 4th quarter valued at $27,000. EverSource Wealth Advisors LLC raised its stake in Protagonist Therapeutics by 138.9% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 540 shares of the company’s stock valued at $36,000 after acquiring an additional 314 shares in the last quarter. Hantz Financial Services Inc. raised its stake in Protagonist Therapeutics by 222.4% during the 4th quarter. Hantz Financial Services Inc. now owns 951 shares of the company’s stock valued at $83,000 after acquiring an additional 656 shares in the last quarter. Finally, Canton Hathaway LLC bought a new stake in Protagonist Therapeutics during the 4th quarter valued at $87,000. Institutional investors own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

PTGX has been the topic of several recent analyst reports. Barclays lifted their target price on Protagonist Therapeutics from $113.00 to $119.00 and gave the company an “overweight” rating in a research note on Thursday, March 19th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a research note on Friday, May 15th. Wall Street Zen raised Protagonist Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Johnson Rice reaffirmed a “buy” rating on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Citizens Jmp lifted their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $115.21.

Read Our Latest Research Report on PTGX

Protagonist Therapeutics Stock Up 0.7%

Shares of Protagonist Therapeutics stock opened at $111.44 on Thursday. The stock’s fifty day moving average is $102.19 and its 200-day moving average is $93.72. The firm has a market capitalization of $7.17 billion, a PE ratio of -61.57 and a beta of 1.85. Protagonist Therapeutics, Inc. has a 12-month low of $49.38 and a 12-month high of $113.66.

Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) last announced its earnings results on Tuesday, May 5th. The company reported $0.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.55. The company had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative return on equity of 17.76% and a negative net margin of 154.88%. Analysts expect that Protagonist Therapeutics, Inc. will post 2.93 EPS for the current year.

Insider Activity at Protagonist Therapeutics

In other news, CFO Asif Ali sold 1,750 shares of the business’s stock in a transaction on Monday, April 20th. The stock was sold at an average price of $105.47, for a total transaction of $184,572.50. Following the sale, the chief financial officer directly owned 59,003 shares of the company’s stock, valued at $6,223,046.41. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Bryan Giraudo sold 6,000 shares of the business’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $100.00, for a total value of $600,000.00. Following the sale, the director directly owned 31,825 shares in the company, valued at $3,182,500. This trade represents a 15.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 272,345 shares of company stock valued at $27,676,386 over the last ninety days. Company insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Profile

(Free Report)

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.